01-22167. New Animal Drugs; Change of Sponsor’s Name and Address  

  • Start Preamble

    AGENCY:

    Food and Drug Administration, HHS.

    ACTION:

    Final rule.

    SUMMARY:

    The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect a change of sponsor’s name and address for Baxter Pharmaceutical Products, Inc.

    DATES:

    This rule is effective September 5, 2001.

    ADDRESSES:

    Lonnie W. Luther, Center for Veterinary Medicine (HFV-102), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-827-0209.

    End Preamble Start Supplemental Information

    SUPPLEMENTARY INFORMATION:

    Baxter Pharmaceutical Products, Inc., 110 Allen Rd., Liberty Corner, NJ 07938, has informed FDA of a change of name and address to Baxter Healthcare Corp., 95 Spring St., New Providence, NJ 07974. Accordingly, the agency is amending the regulations in 21 CFR 510.600(c)(1) and (c)(2) to reflect the changes.

    This rule does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a rule of “particular applicability.” Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808.

    Start List of Subjects

    List of Subjects in 21 CFR Part 510

    End List of Subjects

    Administrative practice and procedure, Animal drugs, Labeling, Reporting and recordkeeping requirements.

    Start Amendment Part

    Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR part 510 is amended as follows:

    End Amendment Part Start Part

    PART 510—NEW ANIMAL DRUGS

    End Part Start Amendment Part

    1. The authority citation for 21 CFR part 510 continues to read as follows:

    End Amendment Part Start Authority

    Authority: 21 U.S.C. 321, 331, 351, 352, 353, 360b, 371, 379e.

    End Authority Start Amendment Part

    2. Section 510.600 is amended in the table in paragraph (c)(1) by revising the entry for “Baxter Pharmaceutical Products, Inc.” and in the table in paragraph (c)(2) by revising the entry for “010019” to read as follows:

    End Amendment Part
    Names, addresses, and drug labeler codes of sponsors of approved applications.
    * * * * *

    (c) * * *

    (1) * * *

    Firm name and addressDrug labeler code
    *         *         *         *         *         *         *
    Baxter Healthcare Corp., 95 Spring St., New Providence, NJ 07974010019
    *         *         *         *         *         *         *

    (2) * * *

    Start Printed Page 46368
    Drug labeler codeFirm name and address
    *         *         *         *         *         *         *
    010019Baxter Healthcare Corp., 95 Spring St., New Providence, NJ 07974
    *         *         *         *         *         *         *
    Start Signature

    Dated: August 23, 2001.

    Claire M. Lathers,

    Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine.

    End Signature End Supplemental Information

    [FR Doc. 01-22167 Filed 9-4-01; 8:45 am]

    BILLING CODE 4160-01-S

Document Information

Effective Date:
9/5/2001
Published:
09/05/2001
Department:
Food and Drug Administration
Entry Type:
Rule
Action:
Final rule.
Document Number:
01-22167
Dates:
This rule is effective September 5, 2001.
Pages:
46367-46368 (2 pages)
PDF File:
01-22167.pdf
CFR: (1)
21 CFR 510.600